Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases

November 29, 2022

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

November 22, 2022

Aclaris Therapeutics Announces Key Leadership Transitions

November 10, 2022

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

Events

Nov 29, 2022
9:30 AM EST

Aclaris Therapeutics at 34th Annual Piper Sandler Healthcare Conference

Nov 16, 2022
5:00 PM GMT

Aclaris Therapeutics at Jefferies London Healthcare Conference

Sep 12, 2022
7:00 AM EDT

Aclaris Therapeutics, Inc. at H.C. Wainwright 24th Annual Global Investment Conference

Feature Presentation

Aclaris Therapeutics Company Overview - August 2022

Aclaris Therapeutics Company Overview - August 2022

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2022 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.